Decitabine for XMEN disease
Treatments studied
Part of Genetic & congenital, Immune system & allergy clinical trials.
This trial tests whether a medicine called decitabine can safely help people with XMEN disease, a rare immune condition. It aims to improve immune function and reduce problems caused by EBV infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Male, between 1 month and 18 years old
- Have a confirmed MAGT1 gene mutation
- Have liver problems or an EBV infection
- Low NKG2D levels on immune cells (confirmed by blood test)
- Be generally healthy enough to survive at least 6 months
- Not have had a stem cell transplant in the last year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (decitabine and venetoclax) at a very low, extended dose for people aged 60 or older who have been newly diagnosed with acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to see if this gentler approach is effective and well-tolerated.
This Phase 2 trial tests whether adding decitabine to one of three targeted medicines (ruxolitinib, fedratinib, or pacritinib) can improve outcomes in people with advanced myeloproliferative neoplasms that are progressing to a blast phase. It may help control the disease by combining blood-cancer chemotherapy with drugs that block disease-driving signaling.
This Phase 1 trial studies how a pill form of decitabine/cedazuridine behaves in the body and how safe it is for people whose livers don’t work normally. It may help doctors better understand dosing and safety in patients with hepatic impairment.
This Phase 1 trial studies how an oral combination cancer medicine behaves in the body (dose handling and safety) in people with kidney impairment. It may help doctors learn the safest way to use this treatment when kidney function is reduced.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
This trial tests whether adding a drug called decitabine to the standard chemo-immunotherapy R-CHOP can help people with a specific type of lymphoma (DLBCL that is positive for EBV) who have not been treated before. The goal is to see if the combination works better than R-CHOP alone.
Hear when a new MAGT1 Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.